Last reviewed · How we verify
live attenuated Japanese encephalitis vaccine
This live attenuated vaccine stimulates immune responses against Japanese encephalitis virus by introducing a weakened form of the virus that replicates but does not cause disease.
This live attenuated vaccine stimulates immune responses against Japanese encephalitis virus by introducing a weakened form of the virus that replicates but does not cause disease. Used for Prevention of Japanese encephalitis.
At a glance
| Generic name | live attenuated Japanese encephalitis vaccine |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a live but attenuated (weakened) strain of Japanese encephalitis virus that can replicate in vaccinated individuals but has reduced pathogenicity. This triggers both cellular and humoral immune responses, including the production of neutralizing antibodies and T-cell immunity against viral antigens. The immune memory generated provides protection against subsequent exposure to wild-type Japanese encephalitis virus.
Approved indications
- Prevention of Japanese encephalitis
Common side effects
- Fever
- Local injection site reactions (pain, erythema, swelling)
- Headache
- Myalgia
Key clinical trials
- Flavivirus Cross-priming Potential of IMOJEV (NA)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity (NA)
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (PHASE2)
- Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province (PHASE4)
- Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects (PHASE3)
- Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: